Maxim 1
2 Parklands Way Holytown
Motherwell ML1 4WR
United Kingdom
44 14 1433 7557
https://tcbiopharm.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 41
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Bryan L. Kobel | CEO & Director | 544.56k | N/D | 1979 |
Mr. Martin E. Thorp | CFO & Director | 410.52k | N/D | 1952 |
Mr. Christopher Camarra | Executive Vice President of Communications | N/D | N/D | N/D |
Dr. Lauren Bor Ph.D. | Head of Commercial Development Division | N/D | N/D | N/D |
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
La calificación ISS Governance QuickScore de TC Biopharm (Holdings) Plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.